$HTBX,
Heat Biologics, Inc. (HTBX) Broker Price Targets For The Coming Week
January 27, 2017 1:25 pm
Writer: Camille Ainsworth
Posted In: US Broker Ratings
Recently analysts working for various investment brokerages have changed their ratings and price targets on shares of Heat Biologics, Inc. (HTBX).
According to the the latest analyst ratings which have been released, 0 brokers have issued a rating of “buy”, 1 brokers “outperform”, 0 brokers “hold”, 0 brokers “underperform” and 0 brokers “sell”.
Recent broker ratings and price targets:
12/09/2016 – Heat Biologics, Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 2 price target on the stock.
08/17/2016 – Noble Financial began new coverage on Heat Biologics, Inc. giving the company a “buy” rating. They now have a USD 8 price target on the stock.
02/04/2016 – Heat Biologics, Inc. was downgraded to “speculative buy” by analysts at Cantor Fitzgerald.
09/03/2015 – Heat Biologics, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 13 price target on the stock.
05/18/2015 – Heat Biologics, Inc. was upgraded to “hold” by analysts at Zacks.
Heat Biologics, Inc. has a 50 day moving average of 0.91 and a 200 day moving average of 1.24. The stock’s market capitalization is 22.45M, it has a 52-week low of 0.40 and a 52-week high of 3.35.
The share price of the company (HTBX) was down -0.19%, with a high of 0.95 during the day and the volume of Heat Biologics, Inc. shares traded was 256189.
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
Receive Heat Biologics, Inc. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics, Inc. with MarketBeat.com's FREE daily email newsletter.
Heat Biologics, Inc. (HTBX) Broker Price Targets For The Coming Week
January 27, 2017 1:25 pm
Writer: Camille Ainsworth
Posted In: US Broker Ratings
Recently analysts working for various investment brokerages have changed their ratings and price targets on shares of Heat Biologics, Inc. (HTBX).
According to the the latest analyst ratings which have been released, 0 brokers have issued a rating of “buy”, 1 brokers “outperform”, 0 brokers “hold”, 0 brokers “underperform” and 0 brokers “sell”.
Recent broker ratings and price targets:
12/09/2016 – Heat Biologics, Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 2 price target on the stock.
08/17/2016 – Noble Financial began new coverage on Heat Biologics, Inc. giving the company a “buy” rating. They now have a USD 8 price target on the stock.
02/04/2016 – Heat Biologics, Inc. was downgraded to “speculative buy” by analysts at Cantor Fitzgerald.
09/03/2015 – Heat Biologics, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 13 price target on the stock.
05/18/2015 – Heat Biologics, Inc. was upgraded to “hold” by analysts at Zacks.
Heat Biologics, Inc. has a 50 day moving average of 0.91 and a 200 day moving average of 1.24. The stock’s market capitalization is 22.45M, it has a 52-week low of 0.40 and a 52-week high of 3.35.
The share price of the company (HTBX) was down -0.19%, with a high of 0.95 during the day and the volume of Heat Biologics, Inc. shares traded was 256189.
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
Receive Heat Biologics, Inc. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics, Inc. with MarketBeat.com's FREE daily email newsletter.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
